<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276495</url>
  </required_header>
  <id_info>
    <org_study_id>UCIANES06</org_study_id>
    <nct_id>NCT02276495</nct_id>
  </id_info>
  <brief_title>Does Single Injection Adductor Canal Block Improve Postoperative Analgesia in Patients Receiving Periarticular Local Anesthesia Injections for Total Knee Arthroplasty?</brief_title>
  <official_title>Does Single Injection Adductor Canal Block Improve Postoperative Analgesia in Patients Receiving Periarticular Local Anesthesia Injections for Total Knee Arthroplasty?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the effect of a single injection adductor canal
      block (ACB) on pain scores within 24 hours post total knee arthroplasty (TKA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score</measure>
    <time_frame>within 24 hours postoperative</time_frame>
    <description>The primary outcome variable of interest is the average maximum pain score within 24 hours postoperative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Use</measure>
    <time_frame>within 24 hours postoperative</time_frame>
    <description>24 Hour post-surgical opioid use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU Opioid Use</measure>
    <time_frame>Postoperative (while in PACU), an expected average of 60 minutes</time_frame>
    <description>PACU opioid use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Opioid Use</measure>
    <time_frame>duration of hospital stay, an expected average of 3 days</time_frame>
    <description>Average daily opioid use during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average NRS Pain Score</measure>
    <time_frame>within 24 hours postoperative</time_frame>
    <description>Average NRS pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>duration of hospital stay, an expected average of 3 days</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>ACB Control + Local Infiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACB Control - 20 ml saline injection for ACB + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB Study + Local infiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACB Study Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ACB Control - 20 ml saline injection for ACB</intervention_name>
    <description>Adductor Canal Block Control (20 ml saline injection)</description>
    <arm_group_label>ACB Control + Local Infiltration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block</intervention_name>
    <description>Adductor Canal Block Study (20 ml 0.5% Ropivacaine)</description>
    <arm_group_label>ACB Study + Local infiltration</arm_group_label>
    <arm_group_label>ACB Study Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline</intervention_name>
    <description>100 mLs of a solution containing:
Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)</description>
    <arm_group_label>ACB Control + Local Infiltration</arm_group_label>
    <arm_group_label>ACB Study + Local infiltration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females age 18+ years old having total knee arthroplasty (TKA) at UCI
             Medical Center

          -  American Society of Anesthesiologists physical status I to III

        Exclusion Criteria:

          -  Allergy to local anesthetics

          -  Pregnancy

          -  Nursing Mothers

          -  Children &lt;18 years of age

          -  Renal impairment (GFR&lt;60 mL/min/1.73m2)

          -  Hepatic Impairment (active hepatitis, elevated AST or ALT, jaundice)

          -  Opioid tolerant patients (defined as greater than 30 mg Morphine equivalent consumed
             daily)

          -  Patients that are diabetic with peripheral neuropathy

          -  BMI greater than 40
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Coral Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Coral Sun, MD</last_name>
    <phone>(714) 456-5501</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecilia Canales, MPH</last_name>
    <phone>(714) 456-8998</phone>
    <email>canalesc@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Coral Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ran Schwarzkopf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyle Ahn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Padma Gulur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane Ahn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Rinehart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Diaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Brown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hao Ho, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wylde V, Rooker J, Halliday L, Blom A. Acute postoperative pain at rest after hip and knee arthroplasty: severity, sensory qualities and impact on sleep. Orthop Traumatol Surg Res. 2011 Apr;97(2):139-44. doi: 10.1016/j.otsr.2010.12.003. Epub 2011 Mar 8.</citation>
    <PMID>21388906</PMID>
  </reference>
  <reference>
    <citation>Robbins SM, Rastogi R, McLaughlin T-L. Predicting Acute Recovery of Physical Function Following Total Knee Joint Arthroplasty. J. Arthroplasty. 2013. Available at: http://www.sciencedirect.com/science/article/pii/S088354031300466X. Accessed December 17, 2013.</citation>
  </reference>
  <reference>
    <citation>Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006 May 13;367(9522):1618-25. Review.</citation>
    <PMID>16698416</PMID>
  </reference>
  <reference>
    <citation>Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Curr Opin Anaesthesiol. 2009 Oct;22(5):588-93. doi: 10.1097/ACO.0b013e328330373a. Review.</citation>
    <PMID>19606021</PMID>
  </reference>
  <reference>
    <citation>Paul JE, Arya A, Hurlburt L, Cheng J, Thabane L, Tidy A, Murthy Y. Femoral nerve block improves analgesia outcomes after total knee arthroplasty: a meta-analysis of randomized controlled trials. Anesthesiology. 2010 Nov;113(5):1144-62. doi: 10.1097/ALN.0b013e3181f4b18. Review.</citation>
    <PMID>20966667</PMID>
  </reference>
  <reference>
    <citation>Feibel RJ, Dervin GF, Kim PR, Beaulé PE. Major complications associated with femoral nerve catheters for knee arthroplasty: a word of caution. J Arthroplasty. 2009 Sep;24(6 Suppl):132-7. doi: 10.1016/j.arth.2009.04.008. Epub 2009 Jun 24.</citation>
    <PMID>19553071</PMID>
  </reference>
  <reference>
    <citation>Jæger P, Zaric D, Fomsgaard JS, Hilsted KL, Bjerregaard J, Gyrn J, Mathiesen O, Larsen TK, Dahl JB. Adductor canal block versus femoral nerve block for analgesia after total knee arthroplasty: a randomized, double-blind study. Reg Anesth Pain Med. 2013 Nov-Dec;38(6):526-32. doi: 10.1097/AAP.0000000000000015.</citation>
    <PMID>24121608</PMID>
  </reference>
  <reference>
    <citation>Mudumbai SC, Kim TE, Howard SK, Workman JJ, Giori N, Woolson S, Ganaway T, King R, Mariano ER. Continuous adductor canal blocks are superior to continuous femoral nerve blocks in promoting early ambulation after TKA. Clin Orthop Relat Res. 2014 May;472(5):1377-83. doi: 10.1007/s11999-013-3197-y.</citation>
    <PMID>23897505</PMID>
  </reference>
  <reference>
    <citation>Ng FY, Ng JK, Chiu KY, Yan CH, Chan CW. Multimodal periarticular injection vs continuous femoral nerve block after total knee arthroplasty: a prospective, crossover, randomized clinical trial. J Arthroplasty. 2012 Jun;27(6):1234-8. doi: 10.1016/j.arth.2011.12.021. Epub 2012 Feb 8.</citation>
    <PMID>22325963</PMID>
  </reference>
  <reference>
    <citation>Teng Y, Jiang J, Chen S, Zhao L, Cui Z, Khan MS, Du W, Gao X, Wang J, Xia Y. Periarticular multimodal drug injection in total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2014 Aug;22(8):1949-57. doi: 10.1007/s00167-013-2566-0. Epub 2013 Jun 20. Review.</citation>
    <PMID>23783531</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Coral Sun</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>pain management for total knee arthroplasty</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

